Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 4916-55-6 | MDL No. : | |
Formula : | - | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | FNHPUOJKUXFUKN-UHFFFAOYSA-N |
M.W : | - | Pubchem ID : | 12707037 |
Synonyms : |
|
Num. heavy atoms : | 9 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.17 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 47.11 |
TPSA : | 12.89 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.15 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 2.39 |
Log Po/w (WLOGP) : | 2.78 |
Log Po/w (MLOGP) : | 1.8 |
Log Po/w (SILICOS-IT) : | 2.4 |
Consensus Log Po/w : | 1.87 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -3.34 |
Solubility : | 0.115 mg/ml ; 0.000456 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.3 |
Solubility : | 1.26 mg/ml ; 0.00499 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.28 |
Solubility : | 0.134 mg/ml ; 0.00053 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 1.73 |
Signal Word: | Class: | ||
Precautionary Statements: | UN#: | ||
Hazard Statements: | Packing Group: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
21% | With caesium carbonate In N,N-dimethyl-formamide at 20℃; Inert atmosphere; | 39.1 Step 1: 1-Benzyl-2-oxo-1,2-dihydropyridin-4-ylboronic acid General procedure: To a solution of 30 mg (0.14 mmol) of 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyridin-2-one and 66 mg (0.20 mmol) of cesium carbonate in 1 ml of anhydrous DMF, are added 18 μl (0.15 mmol) of benzyl bromide at ambient temperature. The reaction is stirred overnight under argon. Reaction mixture is then diluted with ethyl acetate, and the precipitate is filtered and rinsed with a small amount of ethyl acetate. The filtrate is concentrated under vacuum and directly purified by flash chromatography with a 30 g C18 column and a water/acetonitrile mixture as eluent. 20 mg of the title compound are obtained. Yield: 65%. The compound is obtained by the procedure described in example 25 step 1, using 50 mg (0.23 mmol) of4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyridin-2-one, 184 mg (0.57 mmol) of cesium carbonate and 65 mg(0.25 mmol) of 3-(bromomethyl)pyridine hydrobromide instead of benzyl bromide. 11 mg of the title compound areobtained. Yield: 21%. MH+: 231.1. |
[ 1384972-83-1 ]
3-(Bromomethyl)-4-methylpyridine hydrobromide
Similarity: 0.92
[ 1235342-53-6 ]
3-(Bromomethyl)-5-methylpyridine hydrobromide
Similarity: 0.89
[ 73870-24-3 ]
4-(Bromomethyl)pyridine hydrobromide
Similarity: 0.82
[ 1384972-83-1 ]
3-(Bromomethyl)-4-methylpyridine hydrobromide
Similarity: 0.92
[ 1235342-53-6 ]
3-(Bromomethyl)-5-methylpyridine hydrobromide
Similarity: 0.89
[ 73870-24-3 ]
4-(Bromomethyl)pyridine hydrobromide
Similarity: 0.82